Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stephens, A. D.
Right arrow Articles by Sugarbaker, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stephens, A. D.
Right arrow Articles by Sugarbaker, P. H.

Annals of Surgical Oncology, Vol 6, Issue 8 790-796, Copyright © 1999 by Society of Surgical Oncology

ARTICLES

Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique

A. D. Stephens, R. Alderman, D. Chang, G. D. Edwards, J. Esquivel, G. Sebbag, M. A. Steves and P. H. Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA.

BACKGROUND: Peritoneal carcinomatosis from gastrointestinal cancers is a fatal diagnosis without special combined surgical and chemotherapy interventions. Guidelines for cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) by using the Coliseum technique have been developed to treat patients with peritoneal carcinomatosis and other peritoneal surface malignancies. The purpose of this study was to analyze the morbidity and mortality of patients undergoing cytoreductive surgery and HIIC by using mitomycin C. METHODS: Data were prospectively recorded on 183 patients who underwent 200 cytoreductive surgeries with HIIC between November 1994 and June 1998. Seventeen of the 183 patients returned for a second-look surgery plus HIIC. All HIIC administrations occurred after cytoreduction and used continuous manual separation of intra-abdominal structures to optimize drug and heat distribution. Origins of the tumors were as follows: appendix (150 patients), colon (20 patients), stomach (7 patients), pancreas (2 patients), small bowel (1 patient), rectum (1 patient), gallbladder (1 patient), and peritoneal papillary serous carcinoma (1 patient). Morbidity was organized into 20 categories that were graded 0 to IV by the National Cancer Institute's Common Toxicity Criteria. In an attempt to identify patient characteristics that may predispose to complications, each morbidity variable was analyzed for an association with the 25 clinical variables recorded. RESULTS: Combined grade III/IV morbidity was 27.0%. Complications observed included the following: peripancreatitis (6.0%), fistula (4.5%), postoperative bleeding (4.5%), and hematological toxicity (4.0%). Morbidity was statistically linked with the following clinical variables: duration of surgery (P < .0001), the number of peritonectomy procedures and resections (P < .0001), and the number of suture lines (P = .0078). No HIIC variables were statistically associated with the presence of grade III or grade IV morbidity. Treatment-related mortality was 1.5%. CONCLUSIONS: HIIC may be applied to select patients with peritoneal carcinomatosis from gastrointestinal malignancies with 27.0% major morbidity and 1.5% treatment-related mortality. The frequency of complications was associated with the extent of the surgical procedure and not with variables associated with the delivery of heated intraoperative intraperitoneal chemotherapy. The technique has shown an acceptable frequency of adverse events to be tested in phase III adjuvant trials.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
B. L. van Leeuwen, W. Graf, L. Pahlman, and H. Mahteme
Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis
Ann. Surg. Oncol., March 1, 2008; 15(3): 745 - 753.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
N. J. Gusani, S. W. Cho, C. Colovos, S. Seo, J. Franko, S. D. Richard, R. P. Edwards, C. K. Brown, M. P. Holtzman, H. J. Zeh, et al.
Aggressive Surgical Management of Peritoneal Carcinomatosis With Low Mortality in a High-Volume Tertiary Cancer Center
Ann. Surg. Oncol., March 1, 2008; 15(3): 754 - 763.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
W. P. Ceelen, M. Peeters, P. Houtmeyers, C. Breusegem, F. De Somer, and P. Pattyn
Safety and Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with High-Dose Oxaliplatin in Patients with Peritoneal Carcinomatosis
Ann. Surg. Oncol., February 1, 2008; 15(2): 535 - 541.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
L. Benoit, N. Cheynel, P. Ortega-Deballon, G. Di Giacomo, B. Chauffert, and P. Rat
Closed Hyperthermic Intraperitoneal Chemotherapy with Open Abdomen: a Novel Technique to Reduce Exposure of the Surgical Team to Chemotherapy Drugs
Ann. Surg. Oncol., February 1, 2008; 15(2): 542 - 546.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. Kusamura, D. Baratti, A. Antonucci, R. Younan, B. Laterza, G. D. Oliva, C. Gavazzi, and M. Deraco
Incidence of Postoperative Pancreatic Fistula and Hyperamylasemia after Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann. Surg. Oncol., December 1, 2007; 14(12): 3443 - 3452.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
F. Aarts, T. Hendriks, O. C. Boerman, M. J. Koppe, W. J. G. Oyen, and R. P. Bleichrodt
A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats
Ann. Surg. Oncol., November 1, 2007; 14(11): 3274 - 3282.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. Kusamura, D. Baratti, R. Younan, B. Laterza, G. D. Oliva, P. Costanzo, M. Favaro, C. Gavazzi, F. Grosso, and M. Deraco
Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity
Ann. Surg. Oncol., September 1, 2007; 14(9): 2550 - 2558.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. D. Yan, M. Links, S. Fransi, T. Jacques, D. Black, V. Saunders, and D. L. Morris
Learning Curve for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy A Journey to Becoming a Nationally Funded Peritonectomy Center
Ann. Surg. Oncol., August 1, 2007; 14(8): 2270 - 2280.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. Elias, D. Goere, F. Blot, V. Billard, M. Pocard, N. Kohneh-Shahri, and B. Raynard
Optimization of Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin Plus Irinotecan at 43{degrees}C After Compete Cytoreductive Surgery: Mortality and Morbidity in 106 Consecutive Patients
Ann. Surg. Oncol., June 1, 2007; 14(6): 1818 - 1824.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Yan, L Welch, D Black, and P. Sugarbaker
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma
Ann. Onc., May 1, 2007; 18(5): 827 - 834.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. D. Yan, G. Edwards, R. Alderman, C. E. Marquardt, and P. H. Sugarbaker
Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma--A Prospective Study of 70 Consecutive Cases
Ann. Surg. Oncol., February 1, 2007; 14(2): 515 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. D. Yan, E. A. Brun, C. A. Cerruto, N. Haveric, D. Chang, and P. H. Sugarbaker
Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma
Ann. Surg. Oncol., January 1, 2007; 14(1): 41 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. M. Tuttle, Y. Zhang, E. Greeno, and A. Knutsen
Toxicity and Quality of Life after Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy
Ann. Surg. Oncol., December 1, 2006; 13(12): 1627 - 1632.
[Abstract] [Full Text] [PDF]

Home page
 J Public Health (Oxf)Home page
B. J. Moran
Decision-making and technical factors account for the learning curve in complex surgery
J. Public Health Med., December 1, 2006; 28(4): 375 - 378.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. H. Sugarbaker, R. Alderman, G. Edwards, C. E. Marquardt, V. Gushchin, J. Esquivel, and D. Chang
Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy
Ann. Surg. Oncol., May 1, 2006; 13(5): 635 - 644.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
C. Brigand, O. Monneuse, F. Mohamed, A. C. Sayag-Beaujard, S. Isaac, F. N. Gilly, and O. Glehen
Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy: Results of a Prospective Study
Ann. Surg. Oncol., March 1, 2006; 13(3): 405 - 412.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. Deraco, D. Nonaka, D. Baratti, P. Casali, J. Rosai, R. Younan, A. Salvatore, A. D. Cabras, and S. Kusamura
Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
Ann. Surg. Oncol., February 1, 2006; 13(2): 229 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. Younan, S. Kusamura, D. Baratti, G. D. Oliva, P. Costanzo, M. Favaro, C. Gavazzi, and M. Deraco
Bowel Complications in 203 Cases of Peritoneal Surface Malignancies Treated With Peritonectomy and Closed-Technique Intraperitoneal Hyperthermic Perfusion
Ann. Surg. Oncol., November 1, 2005; 12(11): 910 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. H. Stewart IV, P. Shen, and E. A. Levine
Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions
Ann. Surg. Oncol., October 1, 2005; 12(10): 765 - 777.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. H. Sugarbaker, J. T. Mora, P. Carmignani, O. A. Stuart, and D. Yoo
Update on Chemotherapeutic Agents Utilized for Perioperative Intraperitoneal Chemotherapy
Oncologist, February 1, 2005; 10(2): 112 - 122.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Glehen, F. Kwiatkowski, P.H. Sugarbaker, D. Elias, E.A. Levine, M. De Simone, R. Barone, Y. Yonemura, F. Cavaliere, F. Quenet, et al.
Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study
J. Clin. Oncol., August 15, 2004; 22(16): 3284 - 3292.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. A. Ahmad, J. Kim, J. J. Sussman, D. A. Soldano, L. J. Pennington, L. E. James, and A. M. Lowy
Reduced Morbidity Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemoperfusion
Ann. Surg. Oncol., April 1, 2004; 11(4): 387 - 392.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. Shen, J. Hawksworth, J. Lovato, B. W. Loggie, K. R. Geisinger, R. A. Fleming, and E. A. Levine
Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C for Peritoneal Carcinomatosis from Nonappendiceal Colorectal Carcinoma
Ann. Surg. Oncol., February 1, 2004; 11(2): 178 - 186.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
O. Glehen, V. Schreiber, E. Cotte, A. C. Sayag-Beaujard, D. Osinsky, G. Freyer, Y. Francois, J. Vignal, and F. N. Gilly
Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Peritoneal Carcinomatosis Arising From Gastric Cancer
Arch Surg, January 1, 2004; 139(1): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
O. Glehen, D. Osinsky, E. Cotte, F. Kwiatkowski, G. Freyer, S. Isaac, V. Trillet-Lenoir, A.C. Sayag-Beaujard, Y. Francois, J. Vignal, et al.
Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure and Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis: Morbidity and Mortality Analysis of 216 Consecutive Procedures
Ann. Surg. Oncol., October 1, 2003; 10(8): 863 - 869.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. Pilati, S. Mocellin, C. R. Rossi, M. Foletto, L. Campana, D. Nitti, and M. Lise
Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Intraoperative Chemotherapy for Peritoneal Carcinomatosis Arising From Colon Adenocarcinoma
Ann. Surg. Oncol., June 1, 2003; 10(5): 508 - 513.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. J. Canter, R. Mick, S. B. Kesmodel, D. J. Raz, F. R. Spitz, J. M. Metz, E. J. Glatstein, S. M. Hahn, and D. L. Fraker
Intraperitoneal Photodynamic Therapy Causes a Capillary-Leak Syndrome
Ann. Surg. Oncol., June 1, 2003; 10(5): 514 - 524.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
P. Shen, E. A. Levine, J. Hall, D. Case, G. Russell, R. Fleming, R. McQuellon, K. R. Geisinger, and B. W. Loggie
Factors Predicting Survival After Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C After Cytoreductive Surgery for Patients With Peritoneal Carcinomatosis
Arch Surg, January 1, 2003; 138(1): 26 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
O. A. Stuart, A. D. Stephens, L. Welch, and P. H. Sugarbaker
Safety Monitoring of the Coliseum Technique for Heated Intraoperative Intraperitoneal Chemotherapy With Mitomycin C
Ann. Surg. Oncol., March 1, 2002; 9(2): 186 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
P. H. Sugarbaker
Review of a Personal Experience in the Management of Carcinomatosis and Sarcomatosis
Jpn. J. Clin. Oncol., December 1, 2001; 31(12): 573 - 583.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Society of Surgical Oncology.